Hypertrophic and Keloid Scar Treatment Market Size, Trends and Growth Analysis by 2027

The market for treating hypertrophic and keloid scars was valued at approximately US$ 4,498.99 million in 2019 and is anticipated to grow to US$ 9,972.69 million by 2027, reflecting a compound annual growth rate (CAGR) of 10.6% from 2020 to 2027.

Several factors are expected to propel market growth during the forecast period, including the advantages of laser treatments and the rising incidence of injuries. However, challenges such as the lack of universally accessible treatments due to high costs, potential side effects, and limited public awareness may impede market expansion.

Hypertrophic and keloid scars primarily arise from injuries that penetrate deep into the dermis. These injuries can be categorized into various types, including scratches, burns, cuts, gashes, sutures, and surgical incisions. The likelihood of an injury developing into a keloid or hypertrophic scar ranges from 5% to 15%. Additionally, skin conditions like acne and hyperpigmentation can contribute to the formation of these scars. Injuries of different kinds are prevalent across all age demographics, with acne, sports-related injuries, and road accidents being particularly common among younger individuals. Acne is also a significant concern for middle-aged adults, regardless of gender, often exacerbated by hormonal imbalances that can lead to severe scarring. It is estimated that acne affects around 10% of the global population. For example, the American Academy of Dermatology Association reports that acne is the most prevalent skin condition in the United States, impacting approximately 50 million Americans each year, with about 85% of individuals aged 12 to 24 experiencing mild acne issues. The increasing prevalence of acne can be attributed to changing lifestyles, habits, and heightened stress levels, leading to a growing global trend in treating acne-related scars.

According to data from the World Health Organization published in February 2020, injuries from road accidents are the leading cause of death among young adults aged 5 to 29, with around 1.35 million fatalities occurring annually due to such incidents. The rising incidence of severe injuries from road accidents is also contributing to the growing demand for treatments for hypertrophic and keloid scars.

The hypertrophic and keloid scar treatment market is categorized based on scar type into two segments: hypertrophic and keloid scars. In 2019, the hypertrophic segment dominated the market, as these types of scars are more frequently encountered. Hypertrophic scars typically remain within the boundaries of the original wound and tend to diminish over time. Treatment options for hypertrophic scars often involve non-invasive methods such as gels, creams, and silicone sheets for minor injuries, as well as laser therapies. Consequently, this segment is projected to experience a higher CAGR during the forecast period.

When examining product types, the hypertrophic and keloid scar treatment market is divided into laser products, topical treatments, injectables, and other categories. The injectables segment accounted for the largest market share in 2019 and is expected to achieve the highest CAGR throughout the forecast period.

From the perspective of end users, the market is segmented into hospitals, clinics, and homecare settings. The hospital segment held the largest market share in 2019 and is projected to register the highest CAGR during the forecast period.

Key secondary sources utilized in the preparation of the report on the hypertrophic and keloid scar treatment market include the American Society of Plastic Surgeons, the National Academy of Burns-India, the European Medicines Agency, and Nippon Medical School.